Trials / Active Not Recruiting
Active Not RecruitingNCT06544616
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants With Preclinical Alzheimer's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 498 (estimated)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium · Industry
- Sex
- All
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64042056 | JNJ-64042056 will be administered intramuscularly. |
| DRUG | Placebo | Placebo will be administered intramuscularly. |
Timeline
- Start date
- 2024-07-22
- Primary completion
- 2031-07-17
- Completion
- 2032-07-16
- First posted
- 2024-08-09
- Last updated
- 2026-02-17
Locations
90 sites across 9 countries: United States, Australia, Belgium, France, Germany, Japan, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06544616. Inclusion in this directory is not an endorsement.